On August 6, Delcath Systems (NASDAQ:DCTH) reported second-quarter results that showed the company selling more of its liver cancer treatment than ever, even as the cost of running the business climbed just as fast. The interventional oncology company posted total revenue of $29.1 million, up from $24.2 million a year earlier, and used the report to raise its full-year revenue guidance. The numbers tell two stories at once, and investors will need to decide which one matters more.
A Cancer Therapy Gaining Real Traction
Delcath’s growth is coming from HEPZATO KIT, its liver-directed chemotherapy delivery system for metastatic uveal melanoma, which generated $27.1 million in the quarter compared with $22.5 million a year earlier. CHEMOSAT, the European version of the device, added another $2.0 million, up from $1.7 million. HEPZATO procedure volume grew roughly 30% year over year, and the number of active treatment centers using the therapy reached 31, evidence that physician adoption is spreading rather than plateauing. Gross margin widened to 90% from 86%, a sign the business is scaling efficiently as more of each new dollar in HEPZATO sales flows through to the bottom line.
The company backed that momentum by raising its 2026 revenue guidance to a range of $104 million to $108 million, implying HEPZATO volume growth of at least 28% for the full year. It also finished the quarter with $95.9 million in cash and investments and no debt, giving it room to keep expanding without leaning on outside financing. Beyond the current melanoma indication, independent investigators presented retrospective data at ESMO Breast Cancer 2026 showing a 60% hepatic partial response rate in heavily pretreated patients with liver-dominant metastatic breast cancer, and Delcath dosed the first patient in a global Phase 2 trial testing HEPZATO alongside standard of care in that same population. Two additional investigator-led studies, combining HEPZATO with tebentafusp in uveal melanoma and with nivolumab and relatlimab in melanoma that has spread to the liver, were also presented at ASCO 2026.
Growth That Costs More To Chase
The expense side of the ledger grew even faster than revenue. Research and development spending rose to $10.4 million from $6.9 million, which the company attributed to increased clinical headcount and trial activity tied to its expanding pipeline. Selling, general and administrative expenses climbed to $13.4 million from $11.4 million as Delcath kept building out its commercial footprint. Those increases show up directly in profitability: non-GAAP adjusted EBITDA fell to $7.6 million from $9.8 million even though revenue rose nearly 20%, and cash provided by operations dropped to $5.7 million from $7.3 million.
